Remdesivir Shows Promise Against Nipah Virus, Sparking Renewed Research
Nipah virus (NiV) is a highly dangerous zoonotic pathogen, with a fatality rate potentially reaching 70%. First identified in Malaysia in 1998, it continues to cause outbreaks in South and Southeast Asia. A recent outbreak in West Bengal, India, underscores the urgent need for effective antiviral therapies, as no approved vaccine or specific treatment currently exists. The World Health Organization (WHO) is closely monitoring the situation and advising authorities to raise awareness of risk factors 1.
Remdesivir’s Antiviral Activity in Preclinical Studies
A 2019 preclinical study evaluated the antiviral drug remdesivir (GS-5734) in African green monkeys infected with a lethal dose of the Nipah virus Bangladesh genotype. Treatment began 24 hours post-infection and was administered intravenously once daily for 12 days.
The results were significant: all untreated animals developed severe respiratory disease and died, while all animals treated with remdesivir survived. Mild respiratory symptoms were observed in only two treated animals, and their clinical scores returned to baseline within three weeks.
The Role of Cyclodextrin Formulation
An important aspect of remdesivir’s potential efficacy is the drug formulation used in the study. Remdesivir was administered in a vehicle containing 12% sulfobutylether-β-cyclodextrin, a modified cyclodextrin used to improve the solubility and delivery of poorly soluble antiviral compounds. This formulation is crucial for enabling intravenous administration of remdesivir, demonstrating how drug delivery technologies can be essential for translating antiviral molecules into effective therapies.
Current Situation in West Bengal, India
As of February 1, 2026, two confirmed cases of Nipah virus infection have been reported in West Bengal, India, marking the third instance of the virus appearing in the state since 1998 1. Indian authorities are currently tracing over 190 contacts, and, as of this report, none have developed the disease 1. Increased disease surveillance and testing are underway, and the public is being informed about preventative measures.
Nipah Virus: A Resurgent Threat
The recent cases in West Bengal, coupled with the virus’s history of outbreaks in India – including previous occurrences in West Bengal and annual outbreaks in Kerala between 2018 and 2025 – highlight the ongoing threat posed by Nipah virus. The virus is feared to have resurfaced in West Bengal after a gap of 19 years 3. The source of the current infection remains unclear, with preliminary investigations suggesting potential exposure during work-related travel to Purba Bardhaman 3.
Remdesivir Administration in Current Cases
In the current outbreak, two nurses diagnosed with Nipah virus are receiving treatment at a private hospital in Barasat, North 24 Parganas, and are being administered remdesivir, an antiviral drug previously used during the COVID-19 pandemic 2. One patient has reportedly slipped into a coma, while the other remains on ventilator support 1.
Looking Ahead
Given the lack of approved treatments and vaccines for Nipah virus infection, the findings regarding cyclodextrin-formulated remdesivir warrant further investigation as a potential therapeutic option. Continued research and development are crucial to combat this dangerous and resurgent virus.